Is this you? Create Your Porfile
Avatar

Robert Ryan

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Robert Ryan is active.

Explore More

Publication

Featured researches published by Robert Ryan.

Journal of Clinical Oncology | 2017

Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

Bruno C. Medeiros; Donna E. Hogge; Laura F. Newell; Dale Bixby; Scott R. Solomon; Stephen A. Strickland; Tara L. Lin; Harry P. Erba; Bayard L. Powell; Nikolai A. Podoltsev; Robert Ryan; Michael Chiarella; Arthur C. Louie; Jeffrey E. Lancet

Journal of Clinical Oncology | 2017

Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.

Jeffrey E. Lancet; David A. Rizzieri; Gary J. Schiller; Robert K. Stuart; Jonathan E. Kolitz; Scott R. Solomon; Laura F. Newell; Harry P. Erba; Geoffrey L. Uy; Robert Ryan; Michael Chiarella; Arthur C. Louie; Jorge Cortes

Journal of Clinical Oncology | 2018

Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).

Tara L. Lin; Bruno C. Medeiros; Geoffrey L. Uy; Laura F. Newell; Ellen K. Ritchie; Robert K. Stuart; Stephen A. Strickland; Donna E. Hogge; Scott R. Solomon; Richard Stone; Dale Bixby; Jonathan E. Kolitz; Gary J. Schiller; Matthew J. Wieduwilt; Daniel H. Ryan; Robert Ryan; Michael Chiarella; Arthur C. Louie; Jeffrey E. Lancet; Jorge Cortes

Clinical Lymphoma, Myeloma & Leukemia | 2018

Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin

Jonathan E. Kolitz; Stephen A. Strickland; Jorge Cortes; Donna E. Hogge; Jeffrey E. Lancet; Stuart L. Goldberg; Robert Ryan; Michael Chiarella; Arthur C. Louie; Geoffrey L. Uy

Biology of Blood and Marrow Transplantation | 2018

Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program (T-IND)

Stephan A. Grupp; Araz Marachelian; Sonata Jodele; Robert Ryan; Robin Hume; William Tappe; Paul G. Richardson

Biology of Blood and Marrow Transplantation | 2018

Final Analysis of Day +100 Survival by Prior Hematopoietic Stem Cell Transplant Type From an Expanded-Access Study of Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Paul G. Richardson; Angela Smith; Nancy A. Kernan; Leslie Lehmann; Robert Ryan; Robin Hume; William Tappe; Stephan A. Grupp

Biology of Blood and Marrow Transplantation | 2018

Adults Receiving Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results From the Expanded-Access Program (T-IND)

Paul G. Richardson; Joseph H. Antin; Sergio Giralt; Robert Ryan; Wei Liang; Robin Hume; William Tappe; Nancy A. Kernan

Biology of Blood and Marrow Transplantation | 2018

Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)

Paul G. Richardson; Angela Smith; Nancy A. Kernan; Joseph H. Antin; Leslie Lehmann; Robert Ryan; Robin Hume; William Tappe; Stephan A. Grupp

Biology of Blood and Marrow Transplantation | 2018

Efficacy and Safety of Defibrotide in Pediatric Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results From the Expanded-Access Program (T-IND)

Nancy A. Kernan; Angela Smith; Leslie Lehmann; Robert Ryan; Wei Liang; Robin Hume; William Tappe; Stephan A. Grupp

Journal of Clinical Oncology | 2017

Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

Jonathan E. Kolitz; Stephen A. Strickland; Jorge Cortes; Donna E. Hogge; Jeffrey E. Lancet; Stuart L. Goldberg; Karen C. Chung; Robert Ryan; Michael Chiarella; Arthur C. Louie; Robert K. Stuart; Bruno C. Medeiros

Explore More

Collaboration

Dive into the Robert Ryan's collaboration.

Top Co-Authors
Avatar

Arthur C. Louie

Princeton University

View shared research outputs
Top Co-Authors
Avatar

Jeffrey E. Lancet

University of South Florida

View shared research outputs
Top Co-Authors
Avatar

Michael Chiarella

Princeton University

View shared research outputs
Top Co-Authors
Avatar

Nancy A. Kernan

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors
Avatar

Angela Smith

University of Minnesota

View shared research outputs
Top Co-Authors
Avatar

Jonathan E. Kolitz

Hofstra University

View shared research outputs
Top Co-Authors
Avatar

Jorge Cortes

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors
Avatar

Leslie Lehmann

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Paul G. Richardson

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Stephan A. Grupp

Children's Hospital of Philadelphia

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge